Since the introduction of imatinib, the first BCR::ABL1 targeted tyrosine kinase inhibitor (TKI), more than twenty years ago, CML has transformed from a lethal illness to a chronic disease. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.